Objective: The aim of this multicentre study was to determine whether the prophylactic use of intra-aortic balloon pump (IABP) translates into better early and long-term results in high-risk patients undergoing cardiac surgery. Methods: From January 2000 to March 2009, 6121 high-risk patients (EuroSCORE >8), at six different institutions, underwent cardiac surgery. Propensity-score computer matching was performed, based on 10 variables representing patients characteristics and preoperative risk factors to correct for and minimise selection bias (Hosmer-Lemeshow goodness of fit, p = 0.3; c = 0.94). A total of 956 patients were successfully matched and consisted of 478 pairs either undergoing preoperative IABP (group A) or not receiving IABP preoperatively (group B). Results: Multivariate logistic regression (odds ratio) revealed that group B had a 64% higher risk of in-hospital mortality ( p = 0.001), 57% higher risk of 30-day mortality ( p = 0.003), 45% higher risk of perioperative myocardial infarction ( p = 0.01), 57% higher risk of postoperative low-output syndrome ( p = 0.003), 45% higher risk of intensive care unit (ICU) length of stay ( p = 0.001) and 44% higher risk of hospital length of stay ( p = 0.001). Patients in group A showed, at follow-up, significant improvements in left ventricular (LV) ejection fraction ( p < 0.001), wall-motion score index ( p < 0.001) and LV dimensions ( p < 0.001). Five-and 8-year survivals did not differ between groups (5-year survival: 91.7 AE 3.1% vs 95 AE 2.1% in groups A and B, respectively, log-rank p = 0.34; 8-year survival: 84.3 AE 5.5% vs 85.9 AE 6.1% in groups A and B, respectively, log-rank p = 0.2). Conclusions: Prophylactic IABP support, in this multicentre experience, was showed to enhance perioperative management and outcome of high-risk cardiac surgery patients. #
Introduction
Current cardiac surgery programmes are characterised by surgical candidates with older age, more number of preoperative co-morbidities, worse clinical conditions and more depressed left ventricular (LV) function, the so-called 'high-risk patients', as compared to past surgical series. This trend has flattened the beneficial effects of improved surgical techniques, with little or no change in terms of mortality or morbidity particularly in the perioperative phase. Intra-aortic balloon pump (IABP) is the most widely used circulatory-assist device in high-risk patients undergoing cardiac surgery [1] [2] [3] [4] . In these patients, it alleviates myocardial ischaemia prior to circulatory arrest and paves the way for quick postoperative recovery to normal metabolism and less lactate formation [5, 6] .
However, although the introduction of technological improvements has potentially expanded the indications for IABP use [7] , some surgeons have been dissuaded from its wider prophylactic use by reported high IABP-related complication rates [8] . Thus, disagreement about the prophylactic use of IABP and the optimal time of support still exists worldwide, and the need for IABP assistance is still considered to be the witness of a complication rather than a therapeutic tool.
To the best of our knowledge, few large-scale multicentre studies on prophylactic use of IABP have been carried out to date [9] [10] [11] . All of them failed to show a survival benefit deriving from preoperative IABP use [9, 10] . Therefore, it was the objective of this multicentre retrospective study to determine whether the prophylactic use of IABP translates into better early and long-term results in high-risk patients undergoing cardiac surgery.
Methods

Patients
From January 2000 to March 2009, 6121 high-risk patients at six different Italian institutions (Spedali Civili, Brescia; Careggi Hospital, Florence; Ospedale Santa Maria Della Misericordia, Udine; University of Insubria, Varese; Niguarda Hospital, Milano; and Magna Graecia University, Catanzaro) underwent high-risk cardiac surgery.
The number of patients was equally distributed among centres participating in the study.
Data were collected by research assistants who were blinded to the nature of the study and sent to two surgeons (RL and SG), who analysed data and identified high-risk patients. The definition of high-risk patients was based on the European Risk Score System in Cardiac Operations (Euro-SCORE) [12] and the cut-off of !8 was chosen on the basis of the available literature [12, 13] .
Duration of median follow-up was 46 (range: 8-123) months (3284 patient-years).
Ethical issues
In accordance with the World Medical Association guidelines concerning ethical principles for medical research involving human subjects, the study was approved by the Institutional Ethics Board. Approval was also obtained to review records of all high-risk patients undergoing cardiac surgery in order to identify controls. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Preoperative management and IABP insertion
Indications for preoperative IABP were: (1) left main coronary artery disease (>75% stenosis), (2) unstable angina, (3) LV dysfunction with an ejection fraction <35%, (4) recent myocardial infarction and (5) congestive heart failure despite maximal medical treatment. The balloon was inserted under local anaesthesia in the operative room (n = 291) or in cardiac catheterisation laboratory (n = 187). The correct position of the balloon in place was confirmed accordingly by fluoroscopy in the catheterisation laboratory or by trans-oesophageal echocardiography when the balloon was placed in the operating room.
A total of 101 (21.1%) patients underwent percutaneous balloon insertion with the 'sheath-less technique' [14] . The balloons ranged from 7.5 French (F) to 9.5 F (34/40 ml according to the body surface area).
Echocardiographic measurements
Two-dimensional guided M-mode measurements were made preoperatively and at the last follow-up control (mean Table 2 Greedy 5 ! 1 digit match. [15] . The wall-motion-score index (WMSI) was calculated according to a 17-segment model.
Statistical analysis
Pre-matched baseline characteristics of patients are shown in Table 1 . Data were compared with Pearson's chisquare and Wilcoxon rank-sum test for categorical and continuous variables, respectively. To allow an unbiased comparison between high-risk patients (EuroSCORE >8) undergoing prophylactic IABP and those who did not receive a preoperative balloon pump, the propensity-score analysis was employed [15] . The logistic procedure allowed us to calculate the predicted probability (propensity score) of receiving the IABP. Variables considered for inclusion in this model included age, sex, cardiogenic shock, preoperative LVEF, recent myocardial infarction (<15 days), diabetes, preoperative renal insufficiency, urgency/emergency, prior cardiac surgery and left main coronary artery stenosis >70%. The model's reliability and its predictive ability were tested with the Hosmer-Lemeshow (HL) goodness-of-fit test and the C-index, respectively. This model did not show evidence of lack of fit based on the HL statistic ( p = 0.3) and confirmed high discriminative ability (c = 0.94).
The Statistical Analysis Software (SAS) Greedy 5 ! 1 digit match macro was used to identify a matched control for each treated patient according to their propensity score. Adequacy of covariate balance in the matched sample was assessed with McNemar's or Wilcoxon's signed-rank test, which were also employed to assess the differences between treated patients and matched controls for outcome and adverse events, as well as for pre-post comparison within groups. The propensityscore-based greedy-matching algorithm successfully matched 478 treated patients (group A) with a same number of nontreated patients (group B). Adequacy of covariate balance in the matched sample is shown in Table 2 .
Multivariable logistic regression analysis by means of a backward stepwise algorithm (cut-off for entry: 0.05, for removal: 0.10) was performed to select independent predictors of postoperative complications. Categorical variables with more than two levels in the regression model were converted into dummy variables. For regression purposes, intensive care unit (ICU) and in-hospital length of stay (LoS) were treated as categorical variables. The cut-off was chosen as the 75th percentile of values of the entire cohort (ICU LoS: 90 h; in-hospital LoS: 14 days).
Thirty-four variables were chosen based on the existing Society of Thoracic Surgeons (STS) risk-adjustment models and investigated for their predictive value. Nonetheless, to enhance the accuracy of the model, the number of variables were reduced using variable clustering [16] until the number of variables to use as candidates in the regression analysis was m/10, where m is the number of uncensored event times (e.g., deaths) or, for binary outcomes, the number of patients in the less frequent-outcome category. The PROC VARCLUS procedure was employed (SAS/STAT, release 9, SAS Institute, Cary, NC, USA).
Internal validation of predictors generated by multivariable logistic regression was performed by means of bootstrapping techniques, with 1000 cycles and generation of odds ratio (OR) and bias-corrected 95% confidence interval (CI).
Freedom from death was estimated by use of the KaplanMeier method and the log-rank test was employed to detect differences in survival.
We considered a p-value of <0.05 to be statistically significant. Analyses were performed using SAS, release 9.1 (SAS Institute, Cary, NC, USA), SPSS 12.0 (SPSS, Chicago, IL, USA) and Stats Direct 2.5.7 (StatsDirect, Sale, UK) statistical packages. * Appearance of new pathologic Q waves in the coronary distribution of the treated artery with an increase in creatine-kinase-MB to !3 times the reference values OR (non-Q-wave myocardial infarction) was defined as typical ischaemic chest pain and/or ST-segment and/or T-wave abnormalities with creatine-kinase-MB increase !3 times the reference values without new pathologic Q waves.
Results
Early outcome
Early postoperative outcome is shown in Table 3 . Hospital mortality and 30-day mortality were significantly higher in matched controls ( p < 0.001). Need for inotropic support was significantly higher in the non-IABP group. Perioperative myocardial infarction occurred in 23 (4.8%) patients in group B and in nine (1.8%) IABP patients ( p < 0.001); in addition, a higher percentage of patients in group B (7.1% vs 1.9% in IABP, p < 0.001) experienced a low-output syndrome in the postoperative period.
The ICU ( p < 0.001) and the overall length of hospitalisation ( p < 0.001) were significantly lower in patients receiving a preoperative IABP.
IABP-related complications
The mean postoperative IABP time was 2 AE 1.3 days (range: 1-5 days). The overall IABP-related complication rate was 2.5% (95% CI: 1.9-3.1). Seven patients (1.2%) had ischaemia: four underwent removal of distal emboli with Fogarty's arterial embolectomy catheter; in three, the balloon had to be removed. However, all ischaemic events were successfully resolved and none underwent fasciotomy or amputation. Five patients (1.0%) experienced a minor access-site bleeding, and these were successful managed.
Long-term results
Five-and 8-year survivals were not different between groups (5-year survival: 91.7 AE 3.1% vs 95 AE 2.1% in groups A and B, respectively, log-rank p = 0.34; 8-year survival: 84.3 AE 5.5% vs 85.9 AE 6.1% in groups A and B, respectively, log-rank p = 0.2, Fig. 1 ). Furthermore, patients in group A showed, at last follow-up (Fig. 2) , significant improvements in LVEF (36-47%, p < 0.001 vs preoperative, p < 0.001 vs group B), end-systolic diameter (48-32 mm, p < 0.001 vs preoperative, p < 0.001 vs group B), end-diastolic diameter (60-44 mm, p < 0.001 vs preoperative, p < 0.001 vs group B) and wall-motion-score index (1.4-1.06, p < 0.001, p = 0.03 vs group B).
Predictors of postoperative complications
At multivariable logistic regression (Table 4) , the absence of preoperative Intraaortic balloon pump (IABP) was a significant predictive factor of in-hospital mortality ( p < 0.001), 30-day mortality ( p < 0.001), perioperative myocardial infarction ( p = 0.01), postoperative low-output syndrome ( p < 0.001), ICU LoS >90 h ( p < 0.001) and hospital LoS >14 days ( p < 0.001). Specifically, compared with patients with IABP, patients in group B had 64% higher odds for in-hospital death ( p = 0.001), 57% higher odds for 30-day death ( p = 0.003), 45% higher odds for perioperative myocardial infarction ( p = 0.01) and 57% for postoperative low-output syndrome ( p = 0.003). Furthermore, in patients that underwent IABP, ORs for prolonged ICU stay and hospital stay were reduced by 58% ( p = 0.001), and 44%, respectively.
Discussion
With the ageing of the population and improvements in the perioperative management and surgical techniques, a Fig. 1 . Eight-year actuarial survival high-risk patients with prophylactic intraaortic balloon pump (continuous line) and controls (dotted line). Abbreviation: IABP, intra-aortic balloon pump. rising number of high-risk patients undergo cardiac surgery. The intra-aortic balloon pump has been widely used during the perioperative period to support patients with low cardiac output. IABP is the most widely used circulatory-assist device in high-risk patients undergoing cardiac surgery [1] [2] [3] [4] . Use of the IABP has continued to increase, particularly over the past decade with the expansion of interventional cardiology, and the acuity of cardiac surgical patients [1] [2] [3] [4] [5] [6] [7] .
Nonetheless, the prophylactic use of the IABP in cardiac surgery patients is still debated. Data from the Benchmark registry and the STS National Database demonstrated that preoperative IABP therapy was associated with low mortality rates, despite the high-risk status of most of these patients, which corresponds with findings from earlier studies [17, 18] . In contrast, Holman and co-workers [19] reported that preoperative IABP was beneficial, but they did not show survival advantage over post/intra-operative IABP use. However, the patients receiving the balloon pump had improved convalescence as shown by significantly shorter LoS.
In a recent paper, den Uil and co-workers [20] observed, in patients receiving a prophylactic IABP, a decrease in 30-day mortality after CABG. Similarly, a recent single-institutional report showed a significant reduction in-hospital mortality and perioperative acute myocardial infarction in high-risk CABG patients treated with prophylactic IABP [21] . Furthermore, these data agree with both the Benchmark Registry [8] and the STS National Database [22] , both showing a survival advantage whenever preoperative IABP was started in highrisk CABG. Finally, a systematic review by Field et al. [23] showed a beneficial effect of the IABP on mortality and morbidity in specific high-risk patient-groups undergoing CABG.
However, the preoperative IABP support still remains controversial and needs to be elucidated in prospective, randomised studies which, however, are strongly limited by ethical concerns and by the reluctance of many surgeons to an extensive prophylactic use of the IABP.
The propensity-score-matching methods offer a reasonable solution to address the limitation of non-random assignment and reduce the sample-selection bias due to observable differences between the treatment and comparison groups.
In the present multicentre study, we employed the propensity-score analysis to allow an unbiased comparison between high-risk patients (EuroSCORE >8) undergoing prophylactic IABP and those who did not receive a preoperative balloon pump. Based on our reliable model (HL, p = 0.3, c = 0.94), high-risk patients undergoing prophylactic balloon placement before cardiac surgery showed lower in-hospital mortality, lower 30-day mortality and a reduced postoperative incidence of perioperative myocardial infarction and low-output syndrome (all, p < 0.001). Furthermore, patients in group B had lower ICU LoS and inhospital LoS (both p < 0.001). Multivariate logistic regression revealed that group B had a 64% higher risk of in-hospital mortality ( p = 0.001), 57% higher risk of 30-day mortality ( p = 0.003), 45% higher risk of perioperative myocardial infarction ( p = 0.01), 57% higher risk of postoperative lowoutput syndrome ( p = 0.003), 45% higher risk of ICU length of stay >90 h ( p = 0.001) and 44% higher risk of in-hospital LoS >14 days ( p = 0.001).
In our series, the overall IABP-related complication rate was very low (2.5%) and it compared favourably with data from the STS National Database and the Benchmark registry (6.5%) [7, 22] .
Furthermore, survival at 5 and 8 years were not different between groups (log-rank p = 0.34 and log-rank p = 0.2). Nonetheless, patients in group A -differently from those not receiving an IABP support -showed significant improvements in LVEF ( p < 0.001), end-systolic diameter ( p < 0.001), enddiastolic diameter ( p < 0.001) and Wall-motion-score index ( p < 0.001) at follow-up. These data further confirm the reported benefit of preoperative IABP on myocardial function and echocardiographic results at mid-term follow-up [21] .
Clinical considerations
Our findings suggest that patients who undergo high-risk cardiac surgery and prophylactic IABP support have favourable outcomes compared with those who did not have a balloon pump implanted preoperatively. Therefore, liberal use of a prophylactic IABP should be considered in high-risk patients.
Despite this, findings must be interpreted with extreme caution and further studies are warranted to confirm these results; however, some considerations have to be pointedout: first, a limited number of patients in group A had preoperative endocarditis and this may have impacted the worse postoperative outcome of high-risk untreated patients. The use of IABP in endocarditis is still a matter of debate and many surgeons, cardiologists and anaesthesiologists worldwide claim that the insertion of foreign material -such as the intra-aortic balloon into the vascular system of patients with infections -may be harmful. Despite some recent data suggesting a beneficial role of IABP in septic shock [24, 25] , in our opinion, the potential role of IABP in the management of patients with endocarditis needs to be critically evaluated. Our data may suggest that adequate antibiotic coverage together with IABP may be beneficial, as already reported [24, 25] . Second, a limited number of patients with peripheral vascular disease underwent IABP. Indeed, the presence of vascular disease is still considered a contraindication for IABP. In seven patients, the balloon was inserted in an emergency situation as rescue therapy in spite of vasculopathy. On the other hand, the accurate preoperative selection might help to explain the very low incidence of IABP-related complications of our series.
Limitations
This study retains the obvious limitations related to the multicentre and retrospective format of data collection. In particular, the clinical evaluation and procedures were performed at different centres by different surgeons. Furthermore, we did not have information about the time from diagnosis to surgery which might be different between groups.
However, the main limitation is the retrospective nature of this study's non-randomised design. To reduce the bias, we employed the propensity-score analysis. Nonetheless, the adjustment was limited by available variables; thus, the selection bias was not completely eliminated. However, the model did not show evidence of lack of fit based on the HL statistic, and the c-test demonstrated a high discriminative ability.
Conclusions
Even with the above-mentioned limitations, our multicentre experience showed that prophylactic IABP enhanced perioperative outcome of high-risk cardiac surgery patients.
